Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

Inclusion Criteria:

One of the following histologically confirmed diagnoses:

Renal cell cancer

Clear cell histology

Metastatic or unresectable disease AND meets 1 of the following criteria:

Recurrent disease
Refractory to interleukin-2 (IL-2)- or interferon-based therapy
Previously untreated AND not a candidate for IL-2-based therapy

Colorectal, head and neck, pancreatic, or non-small cell lung cancer

Metastatic or unresectable disease
Progression after prior standard treatment

No evidence of CNS disease, including the following (part 2 only):

Primary brain tumor
Brain metastases
Paraffin embedded tumor blocks available
Performance status - ECOG 0-2
Performance status - Karnofsky 60-100%
More than 12 weeks
Absolute neutrophil count ≥ 1,500 mm^3
Platelet count ≥ 100,000 mm^3
Bilirubin ≤ 1.5 mg/dL
AST and ALT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastasis is present)
PTT and INR ≤ 1.5, unless receiving full-dose warfarin (part 2 only)
Creatinine ≤ 1.5 times ULN
Creatinine clearance ≥ 60 mL/min
Calcium < 10 mg/dL (hypocalcemic agents allowed)
No proteinuria*
Protein < 1 g on 24-hour urine collection*
No unstable angina pectoris
No cardiac arrhythmia
No symptomatic congestive heart failure

None of the following are allowed for part 2:

Myocardial infarction within the past 6 months
New York Heart Association class II-IV heart disease
Serious cardiac arrhythmia requiring medication
Peripheral vascular disease ≥ grade II
Recent history of cerebrovascular accident
Uncontrolled hypertension (blood pressure ≥ 150/85 mm Hg despite medication)
Other clinically significant cardiovascular disease
No gastrointestinal (GI) tract disease resulting in an inability to take oral medication
No GI tract disease resulting in a requirement for IV alimentation
No active peptic ulcer disease
No history of allergic reaction attributed to compounds of similar chemical or biologic composition to study drugs
No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies (part 2 only)
No ongoing or active infection
No active infection requiring parenteral antibiotics (part 2 only)
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for 2 months after study treatment
No significant traumatic injury within the past 28 days (part 2 only)
No history of abnormalities of the cornea (e.g., dry eye syndrome, Sjögren's syndrome, or congenital abnormality [e.g., Fuch's dystrophy])
No other malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the breast or cervix
No psychiatric illness or social situation that would preclude study compliance
No serious or non-healing wound ulcer or bone fracture (part 2 only)
No other uncontrolled illness
See Disease Characteristics
More than 4 weeks since prior immunotherapy
No prior cetuximab
No prior bevacizumab
Concurrent epoetin alfa or darbepoetin alfa allowed
More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
More than 4 weeks since prior radiotherapy
No prior surgical procedures affecting absorption
Prior nephrectomy or resection of metastatic lesions allowed provided patient has fully recovered
More than 7 days since prior core biopsy*
More than 28 days since prior major surgery or open biopsy*
No concurrent major surgery*
Recovered from all prior therapy
No prior erlotinib
Concurrent bisphosphonates allowed

Concurrent full-dose anticoagulants allowed provided the following criteria are met (part 2 only):

In-range INR (usually between 2 and 3) AND on a stable dose of warfarin or low molecular weight heparin
No active bleeding
No pathological conditions that carry a high risk of bleeding (e.g., tumor involving major vessels or varices)
No other concurrent investigational agents
No concurrent combination antiretroviral therapy for HIV-positive patients
No other concurrent anticancer therapy